文献速递血栓与止血

血小板减少对心房颤动患者出血及血管事件的影响

Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation.
PubMed 文献 · Blood Adv · 2023-01-01

本研究为倾向评分匹配的回顾性队列研究,纳入2015至2020年间新诊断心房颤动并接受口服抗凝药处方的成人1070例,比较血小板减少(血小板计数<100 000/μL)与血小板正常(>150 000/μL)患者的出血率。

要点

  • 血小板减少组1年大出血累积发生率13.3%,高于对照组的5.7%(P<.0001)。
  • 血小板减少组1年临床相关出血累积发生率24.5%,高于对照组的16.7%(P=.005)。

核心结论

  • 基线血小板计数可能是心房颤动患者出血结局的重要生物标志物,血小板减少程度是确定风险水平的重要因素。

研究设计与样本

  • 倾向评分匹配的回顾性队列研究,纳入2015至2020年间新诊断心房颤动并接受口服抗凝药处方的成人1070例。
  • 血小板减少队列定义为在抗凝起始前12周至起始后6周期间,至少2次不同日期的血小板计数<100 000/μL;对照组为血小板计数>150 000/μL。

主要发现

  • 血小板减少组1年大出血累积发生率为13.3%,对照组为5.7%(P<.0001)。
  • 血小板减少组1年临床相关出血累积发生率为24.5%,对照组为16.7%(P=.005)。
  • 1年动脉血栓累积发生率在血小板减少组为3.6%,对照组为1.5%(Gray检验,P=.08)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whether thrombocytopenia substantively increases the risk of hemorrhage associated with anticoagulation in patients with atrial fibrillation (AF) is not established. The purpose of this study was to compare rates of bleeding in patients with AF and thrombocytopenia (platelet count < 100 000/μL) to patients with AF and normal platelet counts (>150 000/μL). We performed a propensity score-matched, retrospective cohort study of adults (n = 1070) with a new diagnosis of AF who received a prescription for an oral anticoagulant between 2015 and 2020. The thrombocytopenia cohort was defined as having at least 2 platelet counts <100 000/μL on separate days in the period spanning the 12 weeks preceding the initiation of anticoagulation to 6 weeks after the initiation of anticoagulation. The primary end point was the 1-year cumulative incidence of major bleeding; secondary end points included clinically relevant bleeding, arterial and venous thrombotic events, and all-cause mortality. Patients with AF and thrombocytopenia experienced a higher 1-year cumulative incidence of major bleeding (13.3% vs 5.7%; P < .0001) and clinically relevant bleeding (24.5% vs 16.7%; P = .005) than the controls. Thrombocytopenia was identified as an independent risk factor for major bleeding (hazard ratio, 2.20; confidence interval, 1.36-3.58; P = .001), with increasing risk based on the severity of thrombocytopenia. The cumulative incidence of arterial thrombosis at 1 year was 3.6% in the group with thrombocytopenia and 1.5% in controls (Gray test, P = .08). These findings suggest that baseline platelet counts are an important biomarker for hemorrhagic outcomes in AF and that the degree of thrombocytopenia is an important factor in determining the level of risk.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Iyengar V, Patell R, Ren S, et al. Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation. Blood Adv. 2023. PMID: 37756539. doi:10.1182/bloodadvances.2023011235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。